
John Kwon
Examiner (ID: 226, Phone: (571)272-4846 , Office: P/3747 )
| Most Active Art Unit | 3747 |
| Art Unit(s) | 2403, 2605, 3747, 2402, 3745, 3404, 3401, 3754, 3622 |
| Total Applications | 4781 |
| Issued Applications | 4291 |
| Pending Applications | 92 |
| Abandoned Applications | 420 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17044880
[patent_doc_number] => 11098048
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-24
[patent_title] => Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/827136
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15353
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827136
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/827136 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Mar 22, 2020 | Issued |
Array
(
[id] => 16312241
[patent_doc_number] => 20200290979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
[patent_app_type] => utility
[patent_app_number] => 16/815803
[patent_app_country] => US
[patent_app_date] => 2020-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815803
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/815803 | Charged ion channel blockers and methods for use | Mar 10, 2020 | Issued |
Array
(
[id] => 16111485
[patent_doc_number] => 20200207765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION
[patent_app_type] => utility
[patent_app_number] => 16/812703
[patent_app_country] => US
[patent_app_date] => 2020-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -62
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16812703
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/812703 | Methods of preparing inhibitors of influenza viruses replication | Mar 8, 2020 | Issued |
Array
(
[id] => 16090241
[patent_doc_number] => 20200199107
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/810764
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810764
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810764 | Modulators of estrogen receptor proteolysis and associated methods of use | Mar 4, 2020 | Issued |
Array
(
[id] => 18146472
[patent_doc_number] => 20230020329
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/432115
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17432115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/432115 | Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof | Mar 4, 2020 | Abandoned |
Array
(
[id] => 19969654
[patent_doc_number] => 12338246
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => Pyrazine derivative and application thereof in inhibiting SHP2
[patent_app_type] => utility
[patent_app_number] => 17/436223
[patent_app_country] => US
[patent_app_date] => 2020-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23570
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436223
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/436223 | Pyrazine derivative and application thereof in inhibiting SHP2 | Mar 1, 2020 | Issued |
Array
(
[id] => 16268784
[patent_doc_number] => 20200270271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 16/806541
[patent_app_country] => US
[patent_app_date] => 2020-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25891
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806541
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/806541 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Mar 1, 2020 | Pending |
Array
(
[id] => 16222653
[patent_doc_number] => 20200247769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
[patent_app_type] => utility
[patent_app_number] => 16/805252
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805252
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/805252 | Benzothiadiazepine compounds and their use as bile acid modulators | Feb 27, 2020 | Issued |
Array
(
[id] => 17118729
[patent_doc_number] => 11129838
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-28
[patent_title] => Methods of inhibiting pathological angiogenesis
[patent_app_type] => utility
[patent_app_number] => 16/791960
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 34
[patent_no_of_words] => 31040
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791960
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791960 | Methods of inhibiting pathological angiogenesis | Feb 13, 2020 | Issued |
Array
(
[id] => 16012557
[patent_doc_number] => 20200181121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => Cocrystal of Telmisartan and Hydrochlorothiazide
[patent_app_type] => utility
[patent_app_number] => 16/791916
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4275
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791916
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791916 | Cocrystal of Telmisartan and Hydrochlorothiazide | Feb 13, 2020 | Abandoned |
Array
(
[id] => 16012649
[patent_doc_number] => 20200181167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS
[patent_app_type] => utility
[patent_app_number] => 16/791245
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791245
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791245 | Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols | Feb 13, 2020 | Issued |
Array
(
[id] => 16238202
[patent_doc_number] => 20200255436
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/788121
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788121
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/788121 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | Feb 10, 2020 | Abandoned |
Array
(
[id] => 16413254
[patent_doc_number] => 10821115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-03
[patent_title] => Compounds that inhibit Mcl-1 protein
[patent_app_type] => utility
[patent_app_number] => 16/783269
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 102638
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1428
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/783269 | Compounds that inhibit Mcl-1 protein | Feb 5, 2020 | Issued |
Array
(
[id] => 15993285
[patent_doc_number] => 20200172513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/782957
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9095
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782957
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782957 | Dihydropyrimidinyl benzazepine carboxamide compounds | Feb 4, 2020 | Issued |
Array
(
[id] => 15960367
[patent_doc_number] => 20200163935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV
[patent_app_type] => utility
[patent_app_number] => 16/777559
[patent_app_country] => US
[patent_app_date] => 2020-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16777559
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/777559 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | Jan 29, 2020 | Issued |
Array
(
[id] => 17421218
[patent_doc_number] => 11254659
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-02-22
[patent_title] => Capsaicinoid prodrug compounds and their use in treating medical conditions
[patent_app_type] => utility
[patent_app_number] => 16/745689
[patent_app_country] => US
[patent_app_date] => 2020-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23395
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 314
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745689
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/745689 | Capsaicinoid prodrug compounds and their use in treating medical conditions | Jan 16, 2020 | Issued |
Array
(
[id] => 15882795
[patent_doc_number] => 10647729
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-05-12
[patent_title] => Polymorphs of dolutegravir and salts thereof
[patent_app_type] => utility
[patent_app_number] => 16/742326
[patent_app_country] => US
[patent_app_date] => 2020-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 7069
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 4
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742326
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/742326 | Polymorphs of dolutegravir and salts thereof | Jan 13, 2020 | Issued |
Array
(
[id] => 17286242
[patent_doc_number] => 11202780
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-21
[patent_title] => Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
[patent_app_type] => utility
[patent_app_number] => 16/740174
[patent_app_country] => US
[patent_app_date] => 2020-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 24994
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740174
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/740174 | Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide | Jan 9, 2020 | Issued |
Array
(
[id] => 16012653
[patent_doc_number] => 20200181169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => NOVEL POLYMORPHS OF DOLUTEGRAVIR AND SALTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/732992
[patent_app_country] => US
[patent_app_date] => 2020-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7017
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732992
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/732992 | Polymorphs of dolutegravir and salts thereof | Jan 1, 2020 | Issued |
Array
(
[id] => 16156365
[patent_doc_number] => 20200216415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/713601
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 545
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713601
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/713601 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Dec 12, 2019 | Issued |